The invention relates to a method for enhancing the transplantation of hematopoietic cells to supplement or fully reconstitute the hematopoietic system, such as in myeloablated patients or patients otherwise deficient in hematopoietic cells. The method involves administering CD34+ cells having enhanced expression of one or more of AML-1, MYSM1, Hif1a, Profilin-1, phospho-GSK-3beta, SKP2, cbx7, Bmi-1, TCF1, Musashi-2, or FLI1 at levels that provide desirable therapeutically effective amounts of self-renewal of the administered cells and desirable therapeutically effective amounts of differentiation of the administered cells into the various progeny cells of the hematopoietic system (i.e., therapeutically effective amounts of hematopoietic reconstitution). To provide such cells to a subject, the invention relates to detecting such cells prior to or during treatment to ascertain whether such cells are present in clinically-relevant amounts. It may also relate to treating a subject so as to provide clinically-relevant numbers of such cells, as with specific mobilization agents.
